<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7201693</article-id><article-id pub-id-type="doi">10.1155/2020/9519235</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The Prediction and Prognostic Significance of INPP5K Expression in Patients with Liver Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6176-2023</contrib-id><name><surname>Wang</surname><given-names>Ruobing</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6914-7949</contrib-id><name><surname>Jiao</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7030-5537</contrib-id><name><surname>Li</surname><given-names>Yanqing</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Siyang</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Pan</surname><given-names>Guoqiang</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Qin</surname><given-names>Shanshan</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2970-1305</contrib-id><name><surname>Hua</surname><given-names>Fang</given-names></name><email>huafang360@163.com</email><xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4018-5404</contrib-id><name><surname>Liu</surname><given-names>Yahui</given-names></name><email>liuyahui2008@yeah.net</email><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China</aff><aff id="I2">
<sup>2</sup>Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, China</aff><aff id="I3">
<sup>3</sup>Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin 130022, China</aff><aff id="I4">
<sup>4</sup>Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China</aff><aff id="I5">
<sup>5</sup>Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, China</aff><aff id="I6">
<sup>6</sup>Cardiovascular Internal Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Ian R. Ellis</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>25</day><month>4</month><year>2020</year></pub-date><volume>2020</volume><elocation-id>9519235</elocation-id><history><date date-type="received"><day>1</day><month>10</month><year>2019</year></date><date date-type="rev-recd"><day>4</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>13</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Ruobing Wang et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Liver cancer is a devastating disease for humans with poor prognosis. Although the survival rate of patients with liver cancer has improved in the past decades, the recurrence and metastasis of liver cancer are still obstacles for us. Inositol polyphosphate-5-phosphatase K (INPP5K) belongs to the family of phosphoinositide 5-phosphatases (PI 5-phosphatases), which have been reported to be associated with cell migration, polarity, adhesion, and cell invasion, especially in cancers. However, there have been few studies on the correlation of INPP5K and liver cancer. In this study, we explored the prognostic significance of INPP5K in liver cancer through bioinformatics analysis of data collected from The Cancer Genome Atlas (TCGA) database. Chi-square and Fisher exact tests were used to evaluate the relationship between INPP5K expression and clinical characteristics. Our results showed that low INPP5K expression was correlated with poor outcomes in liver cancer patients. Univariate and multivariate Cox analyses demonstrated that low INPP5K mRNA expression played a significant role in shortening overall survival (OS) and relapse-free survival (RFS), which might serve as the useful biomarker and prognostic factor for liver cancer. In conclusion, low INPP5K mRNA expression is an independent risk factor for poor prognosis in liver cancer.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Hepatocellular carcinoma (HCC) is a devastating illness for humans, which has a poor prognosis with a relatively low 5-year survival rate [<xref rid="B1" ref-type="bibr">1</xref>]. Despite therapies for patients with HCC are improving now, the recurrence and metastasis of liver cancer are still unsurmountable obstacles for us. Moreover, it is a great challenge to predict the clinical outcomes for HCC patients. Thus, it is significant to find an effective screening strategy such as new specific markers to identify prognosis for patients.</p><p>INPP5K belongs to the family of PI 5- phosphatase, which catalyze the dephosphorylation of the phosphate of the inositol ring on position 5 [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. It is also known as skeletal muscle and kidney-enriched inositol phosphatase (SKIP) [<xref rid="B4" ref-type="bibr">4</xref>]. INPP5K regulates the actin cytoskeleton, myoblast differentiation and insulin signaling in skeletal muscle [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. Homozygous deletion of INPP5K in mice results in embryonic lethality [<xref rid="B6" ref-type="bibr">6</xref>]. Literatures have reported that mutations in INPP5K were associated with congenital muscular dystrophies, cataract, and intellectual disability [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Recently, PI 5- phosphatase has been reported to be associated with cell migration, polarity, adhesion, and cell invasion, especially in cancer cells. Moreover, the depletion of INPP5K may affect cell migration by the abundance of phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) under the stimulation of integrin [<xref rid="B8" ref-type="bibr">8</xref>]. The above research suggests the role of INPP5K in regulating the motility of cells, which is consistent with the characteristics of tumor metastasis and invasion.</p><p>However, the prognostic significance of INPP5K expression in liver cancer has not been reported yet. In this study, we intend to assess the independent prognostic value of INPP5K expression for overall survival of liver cancer patients. INPP5K expression in liver cancer was obtained from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC). Patients were divided into high and low INPP5K expression groups to explore the correlations between INPP5K expression and different clinical features of liver cancer. Our results indicated that INPP5K might be a biomarker for the diagnosis and prognosis of liver cancer.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Data Mining of TCGA Database</title><p>We collected the RNA-sequencing expression results (level three) from The Cancer Genome Atlas (TCGA) dataset by using R software (version 3.6.1) [<xref rid="B9" ref-type="bibr">9</xref>]. The pathological and clinical information of these patients was gathered following their ID in TCGA dataset. The patients' information included their ages, genders, histological grades, clinical stages, and T/N/M classifications. The INPP5K mRNA expression was evaluated as log2(<italic>x</italic> + 1) scores, which were converted to normalized RNA-Seq by Expectation-Maximization (RSEM) values for the further analysis.</p></sec><sec id="sec2.2"><title>2.2. Data Mining of ICGC Data Portal and GSE14520 Database</title><p>The gene expression results and clinical information of patients were also gathered from the International Cancer Genome Consortium (ICGC, <ext-link ext-link-type="uri" xlink:href="https://icgc.org/">https://icgc.org/</ext-link>) and Gene Expression Omnibus (GEO, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</ext-link>) dataset. The GSE14520 microarray expression information was collected from GEO dataset. The results from TCGA dataset were verified by ICGC and GSE14520 dataset. These data were analyzed by R software.</p></sec><sec id="sec2.3"><title>2.3. Statistical Analyses</title><p>The expression of INPP5K in the TCGA-Liver Hepatocellular Carcinoma (LIHC) dataset was assessed using nonparametric rank sum tests and visualized in box plots. The Wilcoxon rank sum test was performed to analyze the differences between two subgroups, including the gender, age, and vital status. The Kruskal-Wallis test was performed to analyze the differences in three or more subgroups, including the histologic grades, clinical stages, and T/N/M classifications. To explore the relationship between INPP5K mRNA expression and clinical information, we drew the receiver operating characteristic (ROC) curve by using the pROC package [<xref rid="B10" ref-type="bibr">10</xref>]. According to the AUC value identified from the ROC curve, the samples were divided into high/low INPP5K mRNA expression groups. The correlation between clinical parameters and high/low INPP5K mRNA expression was conducted by Chi-square tests and Fisher exact tests. Kaplan-Meier analysis was performed to compare the differences in OS and RFS between high/low INPP5K mRNA expression groups based on the log-rank test using the survival package in R [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Univariate Cox regression analysis was performed to select the potential prognostic factors by calculating the hazard ratios (HRs) and 95 percent confidence intervals (CIs). Multivariate Cox regression analysis was used to verify the correlation of INPP5K mRNA expression with OS and RFS, along with the clinical parameters which were associated with clinical prognosis in univariate analysis. Statistical analysis was conducted with the R software (version 3.6.1). <sup>&#x02217;</sup><italic>P</italic> &#x0003c; 0.05 was considered as significant.</p></sec></sec><sec id="sec3"><title>3. Result</title><sec id="sec3.1"><title>3.1. Patient Characteristics</title><p>Clinical information of 373 patients with liver cancer was downloaded and organized from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC), including age, gender, histological type, histologic grade, TNM classification, radiation therapy, residual tumor status, vital status, sample type, overall survival, and relapse-free survival (<xref rid="tab1" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3.2"><title>3.2. Low INPP5K Expression and Its Diagnostic Value in Liver Cancer</title><p>We compared the expression of INPP5K mRNA in liver cancer (<italic>n</italic> = 373) and normal liver (<italic>n</italic> = 50) tissue via box plots (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The results indicated that INPP5K expression was lower in liver cancer (<italic>P</italic> = 0.013). Consistent with the results in the TCGA cohort, the mRNA expression of INPP5K was significantly downregulated in liver cancer tissues (<italic>n</italic> = 225) when compared with normal liver tissues (<italic>n</italic> = 220) in GSE14520 cohort (<italic>P</italic> &#x02264; 0.0001; Supplementary Fig. <xref ref-type="supplementary-material" rid="supplementary-material-1">S1</xref>).</p><p>The ROC curve was performed using the expression data from TCGA-LIHC to evaluate the diagnostic value of INPP5K (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref>). The area under the ROC curve (AUC) was 0.609, which showed the modest diagnostic value of INPP5K. Subgroup analysis manifested the diagnostic value in different stages of liver cancer with the AUC values of 0.589, 0.622, 0.643, and 0.580 for stage I, stage II, stage III, and stage IV, respectively (Figures <xref ref-type="fig" rid="fig2">2(b)</xref>&#x02013;<xref ref-type="fig" rid="fig2">2(e)</xref>).</p></sec><sec id="sec3.3"><title>3.3. Correlations between Clinical Features and INPP5K Expression in Liver Cancer</title><p>To assess the correlations between INPP5K expression and clinical features of liver cancer, patients were divided into high and low INPP5K mRNA expression groups according to the threshold determined by ROC curve (<xref rid="tab2" ref-type="table">Table 2</xref>). The Chi-square test showed that low INPP5K expression was significantly correlated with survival status (<italic>P</italic> = 0.0276), overall survival (<italic>P</italic> = 0.0236), and relapse-free survival (<italic>P</italic> = 0.0004).</p></sec><sec id="sec3.4"><title>3.4. Low INPP5K Expression Is an Independent Risk Factor for Overall Survival in Liver Cancer Patients</title><p>To evaluate the diagnostic value of INPP5K in liver cancer patients, Kaplan-Meier survival curve with the log-rank test was executed, which indicated that low INPP5K expression was associated with poor overall survival (<italic>P</italic> = 0.0071; <xref ref-type="fig" rid="fig3">Figure 3</xref>). Subgroup analysis showed that low INPP5K expression was correlated with poor overall survival of cases with clinical stage II (<italic>P</italic> = 0.045; <xref ref-type="fig" rid="fig3">Figure 3</xref>). Consistent with the results in the TCGA cohort, the validation of survival analysis was conducted by ICGC cohort (<italic>P</italic> = 0.025; Supplementary Fig. <xref ref-type="supplementary-material" rid="supplementary-material-1">S2</xref>).</p><p>Both univariate and multivariate Cox analyses showed that the expressions of INPP5K (hazard&#x02009;ratio = 1.5, 95% confidence interval: 1.06-2.13, <italic>P</italic> = 0.023), residual tumor (hazard&#x02009;ratio = 1.42, 95% confidence interval: 1.11-1.82, <italic>P</italic> = 0.005), and T classification (hazard&#x02009;ratio = 1.81, 95% confidence interval: 1.44-2.29, <italic>P</italic> &#x02264; 0.001; <xref rid="tab3" ref-type="table">Table 3</xref>) were independent risk factors for poor overall survival in liver cancer patients.</p></sec><sec id="sec3.5"><title>3.5. Low INPP5K Expression Is an Independent Risk Factor for Relapse-Free Survival in Liver Cancer Patients</title><p>To evaluate the diagnostic value of INPP5K in liver cancer patients, Kaplan-Meier survival curve with the log-rank test was executed, which indicated that low INPP5K expression was associated with relapse-free survival (<italic>P</italic> &#x02264; 0.0001; <xref ref-type="fig" rid="fig4">Figure 4</xref>). Subgroup analysis showed that low INPP5K expression was correlated with poor RFS of cases with clinical stage I/II (<italic>P</italic> = 0.0013; <xref ref-type="fig" rid="fig4">Figure 4</xref>) and stage III/IV (<italic>P</italic> = 0.039; <xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>Univariate and multivariate Cox analyses showed that the expression of INPP5K (hazard&#x02009;ratio = 2.03, 95% confidence interval: 1.45-2.83, <italic>P</italic> &#x02264; 0.001), residual tumor (hazard&#x02009;ratio = 1.3, 95% confidence interval: 1.02-1.66, <italic>P</italic> = 0.035), and T classification (hazard&#x02009;ratio = 1.66, 95% confidence interval: 1.27-2.15, <italic>P</italic> &#x02264; 0.001; <xref rid="tab4" ref-type="table">Table 4</xref>) were independent risk factors for RFS in liver cancer patients.</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Liver cancer is associated with a high mortality rate worldwide. Despite the rapid development of medicine, the recurrence and metastasis of liver cancer remain unsolvable. Prognostic markers have numerous potential roles in cancer. They can help to predict patients' outcomes to improve clinical decision-making and screen patients who are most likely to respond to the particular treatment. Therefore, it is important to find reliable biomarkers for diagnosis and prognosis in liver cancer. In recent years, bioinformatics has attracted much attention because of its significance in screening markers. We also have been working on the exploration of tumor biomarkers by bioinformatics [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>].</p><p>In previous studies, some prognostic biomarkers of liver cancers have been identified through bioinformatics. The high mRNA expression of pescadillo (PES1), high mobility group A2 (HMGA2), microtubule-associated serine and threonine kinase 2 (MAST2), trophinin-associated protein (TROAP), and MEX3A was associated with poor prognosis for liver cancer [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B22" ref-type="bibr">22</xref>&#x02013;<xref rid="B25" ref-type="bibr">25</xref>]. Among these biomarkers, MAST2, PES1, and HMGA2 are involved in the regulation of chromosomal instability, DNA replication, cell proliferation, and cell cycle progression. Meanwhile, TROAP and MEX3A are related to the adhesion and cell migration. On the contrary, the low mRNA expression of oxoglutarate dehydrogenase-like (OGDHL) and phosphoglucomutase-like protein 5 (PGM5) was associated with poor prognosis for liver cancer [<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B26" ref-type="bibr">26</xref>]. These two biomarkers, acting as the putative tumor suppressor genes, play prominent roles in regulating the metabolic reprogramming process in cancers.</p><p>In this study, we found that INPP5K was lowly expressed in liver cancer and low expression of the INPP5K mRNA was associated with poor survival status and recurrence in liver cancer. Low INPP5K expression was correlated poor outcomes in liver cancer patients by the Chi-square test. Univariate and multivariate Cox analyses demonstrated that INPP5K mRNA expression played a significant role in overall survival and relapse-free survival, which might be a useful biomarker and prognostic factor for liver cancer. The diagnostic value of INPP5K expression was also confirmed by Kaplan-Meier curves with the log-rank test for OS and RFS.</p><p>PI(4,5)P2, a multifunctional lipid, is essential for regulating several basic subcellular processes in eukaryotic cells. It is also a key lipid messenger that regulates cell migration. Recently, the link between the dynamic balance of PI(4,5)P2 and the mechanisms driving cell polarity and migration has been reported. It participates in the cytoskeletal organization via regulating related proteins (Mena, Tks5, or lamellipodin) [<xref rid="B27" ref-type="bibr">27</xref>]. Moreover, PI(4,5)P2 is involved in dynamic focal adhesion complexes and controls the migration and invasion of various cancer cells [<xref rid="B28" ref-type="bibr">28</xref>&#x02013;<xref rid="B30" ref-type="bibr">30</xref>].</p><p>INPP5K is one of the PI 5-phosphatases, which catalyze the substrates such as PI(4,5)P2 and PI(3,4)P2 [<xref rid="B2" ref-type="bibr">2</xref>]. Similarly like the PI(4,5)P2, PI 5-phosphatases also have been reported to regulate cell migration and invasion in cancer cells. In glioblastoma, the decrease of SH2 domain-containing inositol 5-phosphatase 2 (SHIP2) expression may have a positive or negative effect on cell migration rates depending on the types [<xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B32" ref-type="bibr">32</xref>]. In addition, PI 5-phosphatase SHIP2 or INPP5K can be located on the plasma membrane and reduce the abundance of PI(3,4,5)P3 or PI(4,5)P2 [<xref rid="B8" ref-type="bibr">8</xref>]. Therefore, the association of low INPP5K expression with poor survival in liver cancer patients may be due to the effect of INPP5K on cell migration and invasion by controlling the abundance of P I(4,5)P2. Besides, our results showed that low INPP5K expression correlated significantly with poor RFS in liver cancer cases of nearly all clinical stage except the stage I, which suggested that INPP5K might not regulate the migration at the initiation of tumor formation. As the expression of INPP5K was lower in the deceased than in the living, the relationship between INPP5K and survival needs to be further explored.</p><p>Gene expression and genetic characteristics of tumor are relevant to clinical features, pathological features, and the prognosis of the patients. Data from genomic profiling suggested there are two major molecular clusters (proliferation and nonproliferation) in liver cancer with differential enrichment in prognostic features and the activation of signaling pathway. In the proliferation signaling pathway, the expression of several biomarkers, namely, NOTCH, TGF-<italic>&#x003b2;</italic> proteins, and several genes, is primarily associated with poor prognosis of patients [<xref rid="B33" ref-type="bibr">33</xref>]. It has been reported that the signature of 186 genes in liver cancer surrounding tissues can predict the higher risk of tumor recurrence after resection for liver cancer patients [<xref rid="B34" ref-type="bibr">34</xref>]. And these results are also associated with outcomes of patients with hepatitis C-related early-stage cirrhosis [<xref rid="B35" ref-type="bibr">35</xref>]. In addition, some clinical trials are being conducted based on the high MET expression and the mutations of RAS in tumor cells to find the potential biomarkers for predicting advanced HCC [<xref rid="B36" ref-type="bibr">36</xref>]. These studies suggest the feasibility of conducting tissue biomarker studies in patients with liver cancer. Therefore, the genetic biomarkers correlated with the prognosis of liver cancer should be more widely validated in clinical trials.</p><p>This is the first study that suggested the relationship between INPP5K and clinical characteristics in liver cancer patients by mining TCGA database so far, which indicated that low INPP5K mRNA expression may serve as an independent prognostic factor for poor survival in liver cancer. However, due to sample size limitation, it is difficult to establish a predicting model for INPP5K expression and clinicopathological variables in liver cancer. In further study, we will expand the sample size to explore the prognostic value of INPP5K expression and build an appropriate predicting model for the prognosis of liver cancer patients.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>In this study, we assessed the independent prognostic value of INPP5K expression by mining TCGA database. Our results demonstrated that INPP5K was lowly expressed in liver cancer. The decreased expression level of INPP5K was related to poor prognosis, which could act as an independent risk factor for OS and RFS in liver cancer patients. This finding identified that low INPP5K expression was an independent factor involved in the prognosis of liver cancer and associated with poor survival.</p></sec></body><back><ack><title>Acknowledgments</title><p>To all of those who made this study possible, we express sincere gratitude. Special thanks to colleagues for writing excellent computer programs in R, which supported us to collect and analyze a large amount of data.</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>The data used to support the findings of this study are included within the article.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this paper.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="supp-1"><label>Supplementary Materials</label><caption><p>Figure legends: Supplementary Figure S1: the INPP5K mRNA expression in the GSE14520 cohort. The validation of INPP5K mRNA expression in liver cancer and normal liver tissues was conducted by GSE14520 cohort. Supplementary Figure S2: Kaplan-Meier curves for OS according to INPP5K expression in the ICGC cohort. The validation of survival analysis was conducted by ICGC cohort.</p></caption><media xlink:href="9519235.f1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Naishadham</surname><given-names>D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2013</article-title><source><italic toggle="yes">CA: A Cancer Journal for Clinicians</italic></source><year>2013</year><volume>63</volume><issue>1</issue><fpage>11</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3322/caac.21166</pub-id><pub-id pub-id-type="other">2-s2.0-84872967522</pub-id><?supplied-pmid 23335087?><pub-id pub-id-type="pmid">23335087</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balla</surname><given-names>T.</given-names></name></person-group><article-title>Phosphoinositides: tiny lipids with giant impact on cell regulation</article-title><source><italic toggle="yes">Physiological Reviews</italic></source><year>2013</year><volume>93</volume><issue>3</issue><fpage>1019</fpage><lpage>1137</lpage><pub-id pub-id-type="doi">10.1152/physrev.00028.2012</pub-id><pub-id pub-id-type="other">2-s2.0-84880962133</pub-id><?supplied-pmid 23899561?><pub-id pub-id-type="pmid">23899561</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eramo</surname><given-names>M. J.</given-names></name><name><surname>Mitchell</surname><given-names>C. A.</given-names></name></person-group><article-title>Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases</article-title><source><italic toggle="yes">Biochemical Society Transactions</italic></source><year>2016</year><volume>44</volume><issue>1</issue><fpage>240</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1042/BST20150214</pub-id><pub-id pub-id-type="other">2-s2.0-84958171604</pub-id><?supplied-pmid 26862211?><pub-id pub-id-type="pmid">26862211</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ijuin</surname><given-names>T.</given-names></name><name><surname>Mochizuki</surname><given-names>Y.</given-names></name><name><surname>Fukami</surname><given-names>K.</given-names></name><name><surname>Funaki</surname><given-names>M.</given-names></name><name><surname>Asano</surname><given-names>T.</given-names></name><name><surname>Takenawa</surname><given-names>T.</given-names></name></person-group><article-title>Identification and characterization of a novel inositol polyphosphate 5-phosphatase</article-title><source><italic toggle="yes">The Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>15</issue><fpage>10870</fpage><lpage>10875</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.15.10870</pub-id><pub-id pub-id-type="other">2-s2.0-0034646615</pub-id><?supplied-pmid 10753883?><pub-id pub-id-type="pmid">10753883</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>D. P. S.</given-names></name><name><surname>Pond</surname><given-names>H. L.</given-names></name><name><surname>Mazaheri</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mutations in INPP5K cause a form of congenital muscular dystrophy overlapping Marinesco-Sj&#x000f6;gren syndrome and dystroglycanopathy</article-title><source><italic toggle="yes">American Journal of Human Genetics</italic></source><year>2017</year><volume>100</volume><issue>3</issue><fpage>537</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.019</pub-id><pub-id pub-id-type="other">2-s2.0-85012887864</pub-id><?supplied-pmid 28190459?><pub-id pub-id-type="pmid">28190459</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ijuin</surname><given-names>T.</given-names></name><name><surname>Yu</surname><given-names>Y. E.</given-names></name><name><surname>Mizutani</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Increased insulin action in SKIP heterozygous knockout mice</article-title><source><italic toggle="yes">Molecular and Cellular Biology</italic></source><year>2008</year><volume>28</volume><issue>17</issue><fpage>5184</fpage><lpage>5195</lpage><pub-id pub-id-type="doi">10.1128/MCB.01990-06</pub-id><pub-id pub-id-type="other">2-s2.0-50249182374</pub-id><?supplied-pmid 18573875?><pub-id pub-id-type="pmid">18573875</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiessner</surname><given-names>M.</given-names></name><name><surname>Roos</surname><given-names>A.</given-names></name><name><surname>Munn</surname><given-names>C. J.</given-names></name><etal/></person-group><article-title>Mutations in INPP5K, encoding a phosphoinositide 5-phosphatase, cause congenital muscular dystrophy with cataracts and mild cognitive impairment</article-title><source><italic toggle="yes">American Journal of Human Genetics</italic></source><year>2017</year><volume>100</volume><issue>3</issue><fpage>523</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2017.01.024</pub-id><pub-id pub-id-type="other">2-s2.0-85012866924</pub-id><?supplied-pmid 28190456?><pub-id pub-id-type="pmid">28190456</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>A. R.</given-names></name><name><surname>Elong Edimo</surname><given-names>W.</given-names></name><name><surname>Erneux</surname><given-names>C.</given-names></name></person-group><article-title>Phosphoinositide 5-phosphatase activities control cell motility in glioblastoma: two phosphoinositides PI(4,5)P2 and PI(3,4)P2 are involved</article-title><source><italic toggle="yes">Advances in Biological Regulation</italic></source><year>2018</year><volume>67</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.jbior.2017.09.001</pub-id><pub-id pub-id-type="other">2-s2.0-85029217889</pub-id><?supplied-pmid 28916189?><pub-id pub-id-type="pmid">28916189</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="book"><collab>Team RDCJC</collab><article-title>R : a language and environment for statistical computing</article-title><year>2009</year><publisher-loc>Vienna, Austria</publisher-loc><publisher-name>R Foundation for Statistical Computing</publisher-name></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robin</surname><given-names>X.</given-names></name><name><surname>Turck</surname><given-names>N.</given-names></name><name><surname>Hainard</surname><given-names>A.</given-names></name><etal/></person-group><article-title>pROC: an open-source package for R and S+ to analyze and compare ROC curves</article-title><source><italic toggle="yes">BMC Bioinformatics</italic></source><year>2011</year><volume>12</volume><issue>1</issue><pub-id pub-id-type="doi">10.1186/1471-2105-12-77</pub-id><pub-id pub-id-type="other">2-s2.0-79952709519</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>T. M.</given-names></name></person-group><source><italic toggle="yes">A package for survival analysis in S</italic></source><year>1994</year></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Therneau</surname><given-names>T. M.</given-names></name><name><surname>Grambsch</surname><given-names>P. M.</given-names></name></person-group><source><italic toggle="yes">Modeling Survival Data: Extending the Cox Model</italic></source><year>2000</year><volume>97</volume><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-1-4757-3294-8</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer</article-title><source><italic toggle="yes">Medicine (Baltimore)</italic></source><year>2019</year><volume>98</volume><issue>19, article e15698</issue><pub-id pub-id-type="doi">10.1097/MD.0000000000015698</pub-id><pub-id pub-id-type="other">2-s2.0-85066061028</pub-id><?supplied-pmid 31083274?><pub-id pub-id-type="pmid">31083274</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Meng</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>High EIF2B5 mRNA expression and its prognostic significance in liver cancer: a study based on the TCGA and GEO database</article-title><source><italic toggle="yes">Cancer Management and Research</italic></source><year>2018</year><volume>Volume 10</volume><fpage>6003</fpage><lpage>6014</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S185459</pub-id><pub-id pub-id-type="other">2-s2.0-85057588703</pub-id><?supplied-pmid 30538549?><pub-id pub-id-type="pmid">30538549</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer</article-title><source><italic toggle="yes">PLoS One</italic></source><year>2019</year><volume>14</volume><issue>1, article e0211291</issue><pub-id pub-id-type="doi">10.1371/journal.pone.0211291</pub-id><pub-id pub-id-type="other">2-s2.0-85060781425</pub-id><?supplied-pmid 30695070?><pub-id pub-id-type="pmid">30695070</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>PGM5: a novel diagnostic and prognostic biomarker for liver cancer</article-title><source><italic toggle="yes">PeerJ</italic></source><year>2019</year><volume>7, article e7070</volume><pub-id pub-id-type="doi">10.7717/peerj.7070</pub-id><?supplied-pmid 31218127?><pub-id pub-id-type="pmid">31218127</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>
<italic>ITGA3</italic> serves as a diagnostic and prognostic biomarker for pancreatic cancer</article-title><source><italic toggle="yes">OncoTargets and Therapy</italic></source><year>2019</year><volume>Volume 12</volume><fpage>4141</fpage><lpage>4152</lpage><pub-id pub-id-type="doi">10.2147/OTT.S201675</pub-id><pub-id pub-id-type="other">2-s2.0-85070458653</pub-id><?supplied-pmid 31213833?><pub-id pub-id-type="pmid">31213833</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>High trophinin-associated protein expression is an independent predictor of poor survival in liver cancer</article-title><source><italic toggle="yes">Digestive Diseases and Sciences</italic></source><year>2019</year><volume>64</volume><issue>1</issue><fpage>137</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1007/s10620-018-5315-x</pub-id><pub-id pub-id-type="other">2-s2.0-85054575083</pub-id><?supplied-pmid 30284652?><pub-id pub-id-type="pmid">30284652</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Su</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma</article-title><source><italic toggle="yes">Cancer Management and Research</italic></source><year>2019</year><volume>11</volume><fpage>2795</fpage><lpage>2802</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S196655</pub-id><pub-id pub-id-type="other">2-s2.0-85065083918</pub-id><?supplied-pmid 31114333?><pub-id pub-id-type="pmid">31114333</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>B.</given-names></name><etal/></person-group><article-title>The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer</article-title><source><italic toggle="yes">Bioscience Reports</italic></source><year>2020</year><volume>40</volume><issue>1</issue><pub-id pub-id-type="doi">10.1042/BSR20190729</pub-id><?supplied-pmid 31967298?><pub-id pub-id-type="pmid">31967298</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>B.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical value of lncRNA LUCAT1 expression in liver cancer and its potential pathways</article-title><source><italic toggle="yes">Journal of Gastrointestinal and Liver Diseases</italic></source><year>2019</year><volume>28</volume><issue>4</issue><fpage>439</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.15403/jgld-356</pub-id><?supplied-pmid 31826070?><pub-id pub-id-type="pmid">31826070</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y. Q.</given-names></name><etal/></person-group><article-title>PES1 in liver cancer: a prognostic biomarker with tumorigenic roles</article-title><source><italic toggle="yes">Cancer Management and Research</italic></source><year>2019</year><volume>11</volume><fpage>9641</fpage><lpage>9653</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S226471</pub-id><?supplied-pmid 31814761?><pub-id pub-id-type="pmid">31814761</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y. C.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y. Q.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Z. Y.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name></person-group><article-title>Elevated high mobility group A2 expression in liver cancer predicts poor patient survival</article-title><source><italic toggle="yes">Revista Espa&#x000f1;ola de Enfermedades Digestivas</italic></source><year>2020</year><volume>112</volume><issue>1</issue><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.17235/reed.2019.6365/2019</pub-id><pub-id pub-id-type="pmid">31823639</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>P.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>High MAST2 mRNA expression and its role in diagnosis and prognosis of liver cancer</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2019</year><volume>9</volume><issue>1</issue><fpage>p. 19865</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-56476-x</pub-id><?supplied-pmid 31882722?><pub-id pub-id-type="pmid">31882722</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name></person-group><article-title>Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer</article-title><source><italic toggle="yes">PeerJ</italic></source><year>2020</year><volume>8, article e8252</volume><pub-id pub-id-type="doi">10.7717/peerj.8252</pub-id><?supplied-pmid 31998552?><pub-id pub-id-type="pmid">31998552</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>OGDHL expression as a prognostic biomarker for liver cancer patients</article-title><source><italic toggle="yes">Disease Markers</italic></source><year>2019</year><volume>2019</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">9037131</pub-id><pub-id pub-id-type="doi">10.1155/2019/9037131</pub-id><?supplied-pmid 31781311?><pub-id pub-id-type="pmid">31781311</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>N.</given-names></name><name><surname>Tan</surname><given-names>X.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Lambert</surname><given-names>P. F.</given-names></name><name><surname>Rapraeger</surname><given-names>A. C.</given-names></name><name><surname>Anderson</surname><given-names>R. A.</given-names></name></person-group><article-title>The hidden conundrum of phosphoinositide signaling in cancer</article-title><source><italic toggle="yes">Trends Cancer</italic></source><year>2016</year><volume>2</volume><issue>7</issue><fpage>378</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2016.05.009</pub-id><pub-id pub-id-type="other">2-s2.0-84990062825</pub-id><?supplied-pmid 27819060?><pub-id pub-id-type="pmid">27819060</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>N.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Schramp</surname><given-names>M.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Ling</surname><given-names>K.</given-names></name><name><surname>Anderson</surname><given-names>R. A.</given-names></name></person-group><article-title>Phosphoinositide signaling regulates the exocyst complex and polarized integrin trafficking in directionally migrating cells</article-title><source><italic toggle="yes">Developmental Cell</italic></source><year>2012</year><volume>22</volume><issue>1</issue><fpage>116</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2011.10.030</pub-id><pub-id pub-id-type="other">2-s2.0-84862907595</pub-id><?supplied-pmid 22264730?><pub-id pub-id-type="pmid">22264730</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thapa</surname><given-names>N.</given-names></name><name><surname>Anderson</surname><given-names>R. A.</given-names></name></person-group><article-title>PIP2 signaling, an integrator of cell polarity and vesicle trafficking in directionally migrating cells</article-title><source><italic toggle="yes">Cell Adhesion &#x00026; Migration</italic></source><year>2012</year><volume>6</volume><issue>5</issue><fpage>409</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.4161/cam.21192</pub-id><pub-id pub-id-type="other">2-s2.0-84868115037</pub-id><?supplied-pmid 23076053?><pub-id pub-id-type="pmid">23076053</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Thapa</surname><given-names>N.</given-names></name><name><surname>Hedman</surname><given-names>A. C.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Sacks</surname><given-names>D. B.</given-names></name><name><surname>Anderson</surname><given-names>R. A.</given-names></name></person-group><article-title>IQGAP1 is a novel phosphatidylinositol 4,5 bisphosphate effector in regulation of directional cell migration</article-title><source><italic toggle="yes">The EMBO Journal</italic></source><year>2013</year><volume>32</volume><issue>19</issue><fpage>2617</fpage><lpage>2630</lpage><pub-id pub-id-type="doi">10.1038/emboj.2013.191</pub-id><pub-id pub-id-type="other">2-s2.0-84885177444</pub-id><?supplied-pmid 23982733?><pub-id pub-id-type="pmid">23982733</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edimo</surname><given-names>W. S. E.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Derua</surname><given-names>R.</given-names></name><etal/></person-group><article-title>SHIP2 controls plasma membrane PI(4,5)P2 thereby participating in the control of cell migration in 1321 N1 glioblastoma cells</article-title><source><italic toggle="yes">Journal of Cell Science</italic></source><year>2016</year><volume>129</volume><issue>6</issue><fpage>1101</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1242/jcs.179663</pub-id><pub-id pub-id-type="other">2-s2.0-84961219306</pub-id><?supplied-pmid 26826186?><pub-id pub-id-type="pmid">26826186</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>A. R.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Dedobbeleer</surname><given-names>M.</given-names></name><name><surname>Robe</surname><given-names>P. A.</given-names></name><name><surname>Rogister</surname><given-names>B.</given-names></name><name><surname>Erneux</surname><given-names>C.</given-names></name></person-group><article-title>Lipid phosphatases SKIP and SHIP2 regulate fibronectin-dependent cell migration in glioblastoma</article-title><source><italic toggle="yes">The FEBS Journal</italic></source><year>2019</year><volume>286</volume><issue>6</issue><fpage>1120</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.1111/febs.14769</pub-id><pub-id pub-id-type="other">2-s2.0-85061616893</pub-id><?supplied-pmid 30695232?><pub-id pub-id-type="pmid">30695232</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucman-Rossi</surname><given-names>J.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Nault</surname><given-names>J. C.</given-names></name><name><surname>Llovet</surname><given-names>J. M.</given-names></name></person-group><article-title>Genetic landscape and biomarkers of hepatocellular carcinoma</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2015</year><volume>149</volume><issue>5</issue><fpage>1226</fpage><lpage>1239.e4</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.05.061</pub-id><pub-id pub-id-type="other">2-s2.0-84943232150</pub-id><?supplied-pmid 26099527?><pub-id pub-id-type="pmid">26099527</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshida</surname><given-names>Y.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Kobayashi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Gene expression in fixed tissues and outcome in hepatocellular carcinoma</article-title><source><italic toggle="yes">The New England Journal of Medicine</italic></source><year>2008</year><volume>359</volume><issue>19</issue><fpage>1995</fpage><lpage>2004</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0804525</pub-id><pub-id pub-id-type="other">2-s2.0-57349090407</pub-id><pub-id pub-id-type="pmid">18923165</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshida</surname><given-names>Y.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Sangiovanni</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis</article-title><source><italic toggle="yes">Gastroenterology</italic></source><year>2013</year><volume>144</volume><issue>5</issue><fpage>1024</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.01.021</pub-id><pub-id pub-id-type="other">2-s2.0-84876474584</pub-id><?supplied-pmid 23333348?><pub-id pub-id-type="pmid">23333348</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rimassa</surname><given-names>L.</given-names></name><name><surname>Assenat</surname><given-names>E.</given-names></name><name><surname>Peck-Radosavljevic</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo- controlled study</article-title><source><italic toggle="yes">The Lancet Oncology</italic></source><year>2018</year><volume>19</volume><issue>5</issue><fpage>682</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30146-3</pub-id><pub-id pub-id-type="other">2-s2.0-85044869480</pub-id><?supplied-pmid 29625879?><pub-id pub-id-type="pmid">29625879</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>INPP5K expression in liver cancer. INPP5K expression of liver cancer tissues was compared with that in normal according to age, gender, histological type, histologic grade, TNM classification, radiation therapy, residual tumor status, vital status, sample type, overall survival, and relapse-free survival.</p></caption><graphic xlink:href="BMRI2020-9519235.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The diagnosis value of INPP5K mRNA expression in liver cancer. The ROC curve for INPP5K expression of liver cancer tissues was compared with that in normal. Subgroup analysis for stages I, II, III, and IV liver cancer.</p></caption><graphic xlink:href="BMRI2020-9519235.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Kaplan-Meier curves for OS according to INPP5K expression in liver cancer. Survival analysis and subgroup analysis according to clinical stage were performed based on Kaplan-Meier curves.</p></caption><graphic xlink:href="BMRI2020-9519235.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Kaplan-Meier curves for RFS according to INPP5K expression in liver cancer. Survival analysis and subgroup analysis according to clinical stage were performed based on Kaplan-Meier curves.</p></caption><graphic xlink:href="BMRI2020-9519235.004"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Clinical characteristics of the liver cancer patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="center" rowspan="1" colspan="1">Numbers of cases (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x0003c;55</td><td align="center" rowspan="1" colspan="1">117 (31.45)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02265;55</td><td align="center" rowspan="1" colspan="1">255 (68.55)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">121 (32.44)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">252 (67.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">Histological type</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Fibrolamellar carcinoma</td><td align="center" rowspan="1" colspan="1">3 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hepatocellular carcinoma</td><td align="center" rowspan="1" colspan="1">363 (97.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hepatocholangiocarcinoma (mixed)</td><td align="center" rowspan="1" colspan="1">7 (1.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">Histologic grade</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">5 (1.34)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;G1</td><td align="center" rowspan="1" colspan="1">55 (14.75)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;G2</td><td align="center" rowspan="1" colspan="1">178 (47.72)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;G3</td><td align="center" rowspan="1" colspan="1">123 (32.98)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;G4</td><td align="center" rowspan="1" colspan="1">12 (3.22)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">24 (6.43)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;I</td><td align="center" rowspan="1" colspan="1">172 (46.11)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;II</td><td align="center" rowspan="1" colspan="1">87 (23.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;III</td><td align="center" rowspan="1" colspan="1">85 (22.79)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IV</td><td align="center" rowspan="1" colspan="1">5 (1.34)</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">2 (0.54)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;T1</td><td align="center" rowspan="1" colspan="1">182 (48.79)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;T2</td><td align="center" rowspan="1" colspan="1">95 (25.47)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;T3</td><td align="center" rowspan="1" colspan="1">80 (21.45)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;T4</td><td align="center" rowspan="1" colspan="1">13 (3.49)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;TX</td><td align="center" rowspan="1" colspan="1">1 (0.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">1 (0.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;N0</td><td align="center" rowspan="1" colspan="1">253 (67.83)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;N1</td><td align="center" rowspan="1" colspan="1">4 (1.07)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NX</td><td align="center" rowspan="1" colspan="1">115 (30.83)</td></tr><tr><td align="left" rowspan="1" colspan="1">M classification</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M0</td><td align="center" rowspan="1" colspan="1">267 (71.58)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;M1</td><td align="center" rowspan="1" colspan="1">4 (1.07)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MX</td><td align="center" rowspan="1" colspan="1">102 (27.35)</td></tr><tr><td align="left" rowspan="1" colspan="1">Radiation therapy</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">25 (6.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;No</td><td align="center" rowspan="1" colspan="1">340 (91.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Yes</td><td align="center" rowspan="1" colspan="1">8 (2.14)</td></tr><tr><td align="left" rowspan="1" colspan="1">Residual tumor</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NA</td><td align="center" rowspan="1" colspan="1">7 (1.88)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;R0</td><td align="center" rowspan="1" colspan="1">326 (87.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;R1</td><td align="center" rowspan="1" colspan="1">17 (4.56)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;R2</td><td align="center" rowspan="1" colspan="1">1 (0.27)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;RX</td><td align="center" rowspan="1" colspan="1">22 (5.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vital status</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Deceased</td><td align="center" rowspan="1" colspan="1">130 (34.85)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Living</td><td align="center" rowspan="1" colspan="1">243 (65.15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Sample type</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Primary tumor</td><td align="center" rowspan="1" colspan="1">371 (99.46)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Recurrent tumor</td><td align="center" rowspan="1" colspan="1">2 (0.54)</td></tr><tr><td align="left" rowspan="1" colspan="1">Os_s</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td align="center" rowspan="1" colspan="1">237 (64.58)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">130 (35.42)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rf_s</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;0</td><td align="center" rowspan="1" colspan="1">179 (55.94)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1</td><td align="center" rowspan="1" colspan="1">141 (44.06)</td></tr><tr><td align="left" rowspan="1" colspan="1">INPP5K</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;High</td><td align="center" rowspan="1" colspan="1">225 (60.32)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Low</td><td align="center" rowspan="1" colspan="1">148 (39.68)</td></tr><tr><td align="left" rowspan="1" colspan="1">Type</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">373 (100)</td></tr></tbody></table></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Relationship between the clinical features of liver cancer and INPP5K expression.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">
<italic>N</italic>
</th><th align="center" rowspan="1" colspan="1">High</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">Low</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">X2</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="center" rowspan="1" colspan="1">Fish</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x0003c;55</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">(29.46)</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">(34.46)</td><td align="center" rowspan="1" colspan="1">0.8127</td><td align="center" rowspan="1" colspan="1">0.3673</td><td align="center" rowspan="1" colspan="1">0.3615</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x02265;55</td><td align="center" rowspan="1" colspan="1">255</td><td align="center" rowspan="1" colspan="1">158</td><td align="center" rowspan="1" colspan="1">(70.54)</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">(65.54)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">121</td><td align="center" rowspan="1" colspan="1">75</td><td align="center" rowspan="1" colspan="1">(33.33)</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">(31.08)</td><td align="center" rowspan="1" colspan="1">0.1166</td><td align="center" rowspan="1" colspan="1">0.7327</td><td align="center" rowspan="1" colspan="1">0.7346</td></tr><tr><td align="center" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">252</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">(66.67)</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">(68.92)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Histological type</td><td align="center" rowspan="1" colspan="1">Fibrolamellar carcinoma</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(1.33)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">(0)</td><td align="center" rowspan="1" colspan="1">3.9605</td><td align="center" rowspan="1" colspan="1">0.138</td><td align="center" rowspan="1" colspan="1">0.1695</td></tr><tr><td align="center" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" rowspan="1" colspan="1">363</td><td align="center" rowspan="1" colspan="1">216</td><td align="center" rowspan="1" colspan="1">(96)</td><td align="center" rowspan="1" colspan="1">147</td><td align="center" rowspan="1" colspan="1">(99.32)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">Hepatocholangiocarcinoma (mixed)</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">(2.67)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">(0.68)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Histologic grade</td><td align="center" rowspan="1" colspan="1">G1</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">(17.19)</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">(11.56)</td><td align="center" rowspan="1" colspan="1">4.21</td><td align="center" rowspan="1" colspan="1">0.2397</td><td align="center" rowspan="1" colspan="1">0.2344</td></tr><tr><td align="center" rowspan="1" colspan="1">G2</td><td align="center" rowspan="1" colspan="1">178</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">(49.77)</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">(46.26)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">G3</td><td align="center" rowspan="1" colspan="1">123</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">(29.86)</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">(38.78)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">G4</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">(3.17)</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">(3.4)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">172</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">(51.66)</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">(45.65)</td><td align="center" rowspan="1" colspan="1">1.2996</td><td align="center" rowspan="1" colspan="1">0.7292</td><td align="center" rowspan="1" colspan="1">0.7014</td></tr><tr><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">(24.17)</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">(26.09)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">(22.75)</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">(26.81)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">IV</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(1.42)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(1.45)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="5" colspan="1">T classification</td><td align="center" rowspan="1" colspan="1">T1</td><td align="center" rowspan="1" colspan="1">182</td><td align="center" rowspan="1" colspan="1">115</td><td align="center" rowspan="1" colspan="1">(51.57)</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">(45.27)</td><td align="center" rowspan="1" colspan="1">2.2864</td><td align="center" rowspan="1" colspan="1">0.6832</td><td align="center" rowspan="1" colspan="1">0.7163</td></tr><tr><td align="center" rowspan="1" colspan="1">T2</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">(24.66)</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">(27.03)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">T3</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">(20.18)</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">(23.65)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">T4</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">(3.14)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">(4.05)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">TX</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">(0.45)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">(0)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">N classification</td><td align="center" rowspan="1" colspan="1">N0</td><td align="center" rowspan="1" colspan="1">253</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">(66.96)</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">(69.59)</td><td align="center" rowspan="1" colspan="1">0.5399</td><td align="center" rowspan="1" colspan="1">0.7634</td><td align="center" rowspan="1" colspan="1">0.6991</td></tr><tr><td align="center" rowspan="1" colspan="1">N1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(0.89)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(1.35)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">NX</td><td align="center" rowspan="1" colspan="1">115</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">(32.14)</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">(29.05)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">M classification</td><td align="center" rowspan="1" colspan="1">M0</td><td align="center" rowspan="1" colspan="1">267</td><td align="center" rowspan="1" colspan="1">159</td><td align="center" rowspan="1" colspan="1">(70.67)</td><td align="center" rowspan="1" colspan="1">108</td><td align="center" rowspan="1" colspan="1">(72.97)</td><td align="center" rowspan="1" colspan="1">0.4947</td><td align="center" rowspan="1" colspan="1">0.7809</td><td align="center" rowspan="1" colspan="1">0.7461</td></tr><tr><td align="center" rowspan="1" colspan="1">M1</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(0.89)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(1.35)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">MX</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">(28.44)</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">(25.68)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Radiation therapy</td><td align="center" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">340</td><td align="center" rowspan="1" colspan="1">208</td><td align="center" rowspan="1" colspan="1">(97.65)</td><td align="center" rowspan="1" colspan="1">132</td><td align="center" rowspan="1" colspan="1">(97.78)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">(2.35)</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">(2.22)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Residual tumor</td><td align="center" rowspan="1" colspan="1">R0</td><td align="center" rowspan="1" colspan="1">326</td><td align="center" rowspan="1" colspan="1">198</td><td align="center" rowspan="1" colspan="1">(90.41)</td><td align="center" rowspan="1" colspan="1">128</td><td align="center" rowspan="1" colspan="1">(87.07)</td><td align="center" rowspan="1" colspan="1">2.7596</td><td align="center" rowspan="1" colspan="1">0.4302</td><td align="center" rowspan="1" colspan="1">0.4237</td></tr><tr><td align="center" rowspan="1" colspan="1">R1</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">(3.65)</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">(6.12)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">R2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">(0)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">(0.68)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">RX</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">(5.94)</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">(6.12)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Vital status</td><td align="center" rowspan="1" colspan="1">Deceased</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">(30.22)</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">(41.89)</td><td align="center" rowspan="1" colspan="1">4.8529</td><td align="center" rowspan="1" colspan="1">
<bold>0.0276</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.0262</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">Living</td><td align="center" rowspan="1" colspan="1">243</td><td align="center" rowspan="1" colspan="1">157</td><td align="center" rowspan="1" colspan="1">(69.78)</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">(58.11)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Sample type</td><td align="center" rowspan="1" colspan="1">Primary tumor</td><td align="center" rowspan="1" colspan="1">371</td><td align="center" rowspan="1" colspan="1">225</td><td align="center" rowspan="1" colspan="1">(100)</td><td align="center" rowspan="1" colspan="1">146</td><td align="center" rowspan="1" colspan="1">(98.65)</td><td align="center" rowspan="1" colspan="1">1.0481</td><td align="center" rowspan="1" colspan="1">0.3059</td><td align="center" rowspan="1" colspan="1">0.1568</td></tr><tr><td align="center" rowspan="1" colspan="1">Recurrent tumor</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">(0)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">(1.35)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Os_s</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">237</td><td align="center" rowspan="1" colspan="1">154</td><td align="center" rowspan="1" colspan="1">(69.37)</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">(57.24)</td><td align="center" rowspan="1" colspan="1">5.1222</td><td align="center" rowspan="1" colspan="1">
<bold>0.0236</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.0193</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">130</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">(30.63)</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">(42.76)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Rf_s</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">179</td><td align="center" rowspan="1" colspan="1">125</td><td align="center" rowspan="1" colspan="1">(64.1)</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">(43.2)</td><td align="center" rowspan="1" colspan="1">12.668</td><td align="center" rowspan="1" colspan="1">
<bold>0.0004</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.0003</bold>
</td></tr><tr><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">141</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">(35.9)</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">(56.8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate and multivariate analyses of the correlation of INPP5K expression with OS among liver cancer patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Parameters</th><th align="center" colspan="3" rowspan="1">Univariate analysis</th><th align="center" colspan="3" rowspan="1">Multivariate analysis</th></tr><tr><th align="center" rowspan="1" colspan="1">Hazard.Ratio.x</th><th align="center" rowspan="1" colspan="1">CI95.x</th><th align="center" rowspan="1" colspan="1">Pvalue.x</th><th align="center" rowspan="1" colspan="1">Hazard.Ratio.y</th><th align="center" rowspan="1" colspan="1">CI95.y</th><th align="center" rowspan="1" colspan="1">Pvalue.y</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.69-1.45</td><td align="center" rowspan="1" colspan="1">0.997</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">0.80</td><td align="center" rowspan="1" colspan="1">0.56-1.14</td><td align="center" rowspan="1" colspan="1">0.220</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histological type</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.27-3.66</td><td align="center" rowspan="1" colspan="1">0.986</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic grade</td><td align="center" rowspan="1" colspan="1">1.04</td><td align="center" rowspan="1" colspan="1">0.84-1.30</td><td align="center" rowspan="1" colspan="1">0.698</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1">1.38</td><td align="center" rowspan="1" colspan="1">1.15-1.66</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.70-1.08</td><td align="center" rowspan="1" colspan="1">0.205</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.39-1.99</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" rowspan="1" colspan="1">1.81</td><td align="center" rowspan="1" colspan="1">1.44-2.29</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification</td><td align="center" rowspan="1" colspan="1">0.73</td><td align="center" rowspan="1" colspan="1">0.51-1.05</td><td align="center" rowspan="1" colspan="1">0.086</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">M classification</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.49-1.04</td><td align="center" rowspan="1" colspan="1">0.077</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Radiation therapy</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">0.26-1.03</td><td align="center" rowspan="1" colspan="1">0.060</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Residual tumor</td><td align="center" rowspan="1" colspan="1">1.42</td><td align="center" rowspan="1" colspan="1">1.13-1.80</td><td align="center" rowspan="1" colspan="1">
<bold>0.003</bold>
</td><td align="center" rowspan="1" colspan="1">1.42</td><td align="center" rowspan="1" colspan="1">1.11-1.82</td><td align="center" rowspan="1" colspan="1">
<bold>0.005</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">INPP5K</td><td align="center" rowspan="1" colspan="1">1.61</td><td align="center" rowspan="1" colspan="1">1.13-2.28</td><td align="center" rowspan="1" colspan="1">
<bold>0.008</bold>
</td><td align="center" rowspan="1" colspan="1">1.50</td><td align="center" rowspan="1" colspan="1">1.06-2.13</td><td align="center" rowspan="1" colspan="1">
<bold>0.023</bold>
</td></tr></tbody></table></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Univariate and multivariate analyses of the correlation of INPP5K expression with RFS among liver cancer patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Parameters</th><th align="center" colspan="3" rowspan="1">Univariate analysis</th><th align="center" colspan="3" rowspan="1">Multivariate analysis</th></tr><tr><th align="center" rowspan="1" colspan="1">Hazard.Ratio.x</th><th align="center" rowspan="1" colspan="1">CI95.x</th><th align="center" rowspan="1" colspan="1">Pvalue.x</th><th align="center" rowspan="1" colspan="1">Hazard.Ratio.y</th><th align="center" rowspan="1" colspan="1">CI95.y</th><th align="center" rowspan="1" colspan="1">Pvalue.y</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">0.90</td><td align="center" rowspan="1" colspan="1">0.63-1.28</td><td align="center" rowspan="1" colspan="1">0.550</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">0.99</td><td align="center" rowspan="1" colspan="1">0.70-1.41</td><td align="center" rowspan="1" colspan="1">0.966</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histological type</td><td align="center" rowspan="1" colspan="1">2.02</td><td align="center" rowspan="1" colspan="1">0.66-6.24</td><td align="center" rowspan="1" colspan="1">0.220</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic grade</td><td align="center" rowspan="1" colspan="1">0.98</td><td align="center" rowspan="1" colspan="1">0.80-1.21</td><td align="center" rowspan="1" colspan="1">0.883</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.38-1.99</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" rowspan="1" colspan="1">1.11</td><td align="center" rowspan="1" colspan="1">0.86-1.43</td><td align="center" rowspan="1" colspan="1">0.416</td></tr><tr><td align="left" rowspan="1" colspan="1">T classification</td><td align="center" rowspan="1" colspan="1">1.78</td><td align="center" rowspan="1" colspan="1">1.49-2.12</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" rowspan="1" colspan="1">1.66</td><td align="center" rowspan="1" colspan="1">1.27-2.15</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">N classification</td><td align="center" rowspan="1" colspan="1">0.97</td><td align="center" rowspan="1" colspan="1">0.67-1.40</td><td align="center" rowspan="1" colspan="1">0.874</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">M classification</td><td align="center" rowspan="1" colspan="1">1.17</td><td align="center" rowspan="1" colspan="1">0.79-1.74</td><td align="center" rowspan="1" colspan="1">0.432</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Radiation therapy</td><td align="center" rowspan="1" colspan="1">0.74</td><td align="center" rowspan="1" colspan="1">0.26-2.16</td><td align="center" rowspan="1" colspan="1">0.584</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Residual tumor</td><td align="center" rowspan="1" colspan="1">1.28</td><td align="center" rowspan="1" colspan="1">1.01-1.61</td><td align="center" rowspan="1" colspan="1">
<bold>0.042</bold>
</td><td align="center" rowspan="1" colspan="1">1.30</td><td align="center" rowspan="1" colspan="1">1.02-1.66</td><td align="center" rowspan="1" colspan="1">
<bold>0.035</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">INPP5K</td><td align="center" rowspan="1" colspan="1">2.09</td><td align="center" rowspan="1" colspan="1">1.50-2.90</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td align="center" rowspan="1" colspan="1">2.03</td><td align="center" rowspan="1" colspan="1">1.45-2.83</td><td align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr></tbody></table></table-wrap></floats-group></article>